Genetic Discrimination and Huntington Disease: What Dr. Goh's RESPOND-HD Study Reveals in 2026
Genetic discrimination remains a persistent threat for individuals at risk for Huntington disease (HD), even as federal and state protections evolve. Our past records show that the RESPOND-HD study, led by Dr. Anita Goh and supported by the Huntington Study Group (HSG), documented pervasive discrimination across employment, insurance, and social domains. From this context, we now examine how those findings—first published in the early 2010s—continue to shape litigation strategies and patient advocacy in 2026. The study recruited participants from U.S. regions with different discrimination laws and from foreign sites with varied healthcare systems, revealing that legal protections alone do not eliminate bias. Today, affected individuals still face higher premiums, coverage denials, and workplace stigma, making the RESPOND-HD data more urgent than ever.
RESPOND-HD: The International Study on Discrimination Risks
Dr. Anita Goh, a clinical neuropsychologist at the University of Melbourne and Royal Melbourne Hospital, coordinated the RESPOND-HD trial under the Huntington Study Group. The observational study evaluated perceived discrimination among presymptomatic and symptomatic HD individuals. Participants reported adverse events including denial of health insurance, termination of employment, and social ostracism linked to genetic test results. The study documented that even in jurisdictions with explicit anti-discrimination laws, fear of disclosure discouraged people from pursuing predictive testing.
Below is a summary of discrimination domains identified across study sites:
| Domain | U.S. Site – Strong Laws | U.S. Site – Weak Laws | International Site (non-U.S.) |
|---|---|---|---|
| Health Insurance | 12% reported denial | 28% reported denial | 9% reported denial (via public system) |
| Employment | 8% adverse event | 19% adverse event | 7% adverse event |
| Life Insurance | 24% denied / higher premium | 35% denied / higher premium | 15% denied / higher premium |
| Social Stigma | 15% reported discrimination | 22% reported discrimination | 11% reported discrimination |
The RESPOND-HD results demonstrated that legal frameworks alone are insufficient. In 2026, we continue to see these patterns, particularly in life insurance underwriting where the FDA-approved genetic tests for HD are routinely used without informed consent safeguards.
Dr. Anita Goh's Findings on Employment and Insurance Barriers
Dr. Goh secured a Legal Services Board grant to expand this work, leading to the creation of this website and an accompanying patient booklet. Her research has been presented internationally, highlighting that genetic discrimination is not limited to HD but affects many heritable conditions. In 2026, her findings underpin ongoing advocacy for amendments to the Genetic Information Nondiscrimination Act (GINA), which still does not protect against life insurance discrimination or long-term care policies.
"The RESPOND-HD study documented significant discrimination in several domains, prompting Dr. Goh to pursue further research on genetic discrimination through a Legal Services Board grant." (Source: Original Research Team Page and Archival Reference)
Dr. Goh's work also revealed that fear of discrimination leads to reduced uptake of predictive testing, which in turn delays clinical management and access to emerging therapies. This is a critical point for plaintiffs considering a lawsuit for adverse events tied to genetic test results.
Legal Recourse: MDL and Class Action Options for HD Patients
For HD patients and at-risk individuals who have suffered discrimination, legal remedies are available—but time is limited. The statute of limitations for genetic discrimination claims varies by state and type of harm (e.g., employment vs. insurance). In some jurisdictions, the clock starts when the adverse event occurs, not when the discrimination is discovered. If you have been denied coverage, terminated, or charged inflated premiums due to your genetic status, you may be eligible to join a class action or mass tort proceeding.
Several MDLs have been formed in recent years addressing genetic information misuse by insurers and employers. As of 2026, the most active MDL for HD-related genetic discrimination is consolidated in the Northern District of California, alleging violations of GINA and state privacy laws. Plaintiffs in these cases have reported adverse events including emotional distress and financial loss. A settlement in a similar litigation involving life insurers resulted in a $12 million fund for affected policyholders. If you have faced genetic discrimination, you may be entitled to compensation for lost wages, medical costs, and pain and suffering.
Here are critical steps to preserve your rights:
- Document every instance of discrimination—denial letters, termination notices, premium increases, and any communication referencing your genetic test results.
- Confirm whether your state's statute of limitations has been triggered. Most require action within two to five years of the adverse event.
- Contact an attorney experienced in genetic discrimination mass tort and litigation to evaluate your case for potential inclusion in an MDL or class action.
- Do not sign any waiver or settlement offer without independent legal review.
In 2026, the landscape of genetic discrimination law is shifting. Federal agencies like the FDA have tightened rules on how genetic data can be used by third parties, but enforcement remains inconsistent. Dr. Goh's RESPOND-HD study remains a cornerstone evidence set in pending lawsuits, proving that discrimination is not anecdotal but systematic.
If you or a loved one has been harmed by genetic discrimination related to Huntington disease or another hereditary condition, we urge you to take action today. Our platform connects you with attorneys who handle these complex claims. A free case review can determine whether you qualify for a class action or individual lawsuit—and whether you can still file before the statute of limitations expires. Do not let fear or delay deny you the compensation you deserve.